Open access · CC-BY
via OpenAlex
HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease
Barry W. Festoff, Ravi Kiran Sajja, Patrick Van Dreden, Luca Cucullo
Journal of Neuroinflammation · 2016 · ▲ 214 citations
Abstract
BACKGROUND: The blood-brain barrier (BBB) dysfunction represents an early feature of Alzheimer's disease (AD) that precedes the hallmarks of amyloid beta (amyloid β) plaque deposition and neuronal neurofibrillary tangle (NFT) formation. A damaged BBB correlates directly with neuroinflammation involving microglial activation and reactive astrogliosis, which is associated with increased expression and/or release of high-mobility group box protein 1 (HMGB1) and thrombin. However, the link between the presence of these molecules, BBB damage, and progression to neurodegeneration in AD is still elusive. Therefore, we aimed to profile and validate non-invasive clinical biomarkers of BBB dysfunction and neuroinflammation to assess the progression to neurodegeneration in mild cognitive impairment (MCI) and AD patients. METHODS: We determined the serum levels of various proinflammatory damage-associated molecules in aged control subjects and patients with MCI or AD using validated ELISA kits. We then assessed the specific and direct effects of such molecules on BBB integrity in vitro using human primary brain microvascular endothelial cells or a cell line. RESULTS: We observed a significant increase in serum HMGB1 and soluble receptor for advanced glycation end products (sRAGE) that correlated well with amyloid beta levels in AD patients (vs. control subjects). Interestingly, serum HMGB1 levels were significantly elevated in MCI patients compared to controls or AD patients. In addition, as a marker of BBB damage, soluble thrombomodulin (sTM) antigen, and activity were significantly (and distinctly) increased in MCI and AD patients. Direct in vitro BBB integrity assessment further revealed a significant and concentration-dependent increase in paracellular permeability to dextrans by HMGB1 or α-thrombin, possibly through disruption of zona occludins-1 bands. Pre-treatment with anti-HMGB1 monoclonal antibody blocked HMGB1 effects and leaving BBB integrity intact. CONCLUSIONS: Our current studies indicate that thrombin and HMGB1 are causal proximate proinflammatory mediators of BBB dysfunction, while sTM levels may indicate BBB endothelial damage; HMGB1 and sRAGE might serve as clinical biomarkers for progression and/or therapeutic efficacy along the AD spectrum.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s12974-016-0670-z
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Festoff, B.W., Sajja, R.K., Dreden, P.V., & Cucullo, L. (2016). HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease. <em>Journal of Neuroinflammation</em>. https://doi.org/10.1186/s12974-016-0670-z
Vancouver
Festoff BW, Sajja RK, Dreden PV, Cucullo L. HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease. Journal of Neuroinflammation. 2016. doi:10.1186/s12974-016-0670-z.
BibTeX
@article{barry2016HMGBan,
title = {HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease},
author = {Barry W. Festoff and Ravi Kiran Sajja and Patrick Van Dreden and Luca Cucullo},
journal = {Journal of Neuroinflammation},
year = {2016},
doi = {10.1186/s12974-016-0670-z},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Molecular Neurodegeneration 2015
Open access · CC-BY
Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay
Molecular Medicine 2020
Open access · CC-BY
Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer’s disease
Journal of Neuroscience 2013
Open access · CC-BY
Tau Accumulation Activates the Unfolded Protein Response by Impairing Endoplasmic Reticulum-Associated Degradation
PubMed 1994
Preprint
Brain interleukin-1 beta in Alzheimer's disease and vascular dementia.
Frontiers in Molecular Neuroscience 2017
Open access · CC-BY
Increased White Matter Inflammation in Aging- and Alzheimer’s Disease Brain
Current Medicinal Chemistry 2014
Citation only